By Sabela Ojea

BioMarin Pharmaceutical said the Food and Drug Administration has approved its new drug application to treat all pediatric patients with a growth condition.

The biotechnology company on Friday said its Voxzogo treatment is aimed at increasing linear growth and has been approved based on an improvement in annualized growth velocity.

The medication had previously been indicated for achondroplasia patients who were 5 years of age and older.

Voxzogo is currently approved in Europe for children with achondroplasi who are at least 2 years old.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

October 20, 2023 16:39 ET (20:39 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas BioMarin Pharmaceutical.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas BioMarin Pharmaceutical.